ArticleBMC gastroenterology2025
Development and validation of a nomogram for predicting endoscopic healing in crohn's disease patients receiving infliximab treatment.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of a predictive nomogram for response to biologics and targeted therapy in Crohn's disease: a retrospective cohort study.Frontiers in immunology · 2026Article
- Relationship between serum total bilirubin levels and primary loss of response to Infliximab therapy in Crohn's disease patients.BMC gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe objective of this study was to identify prognostic clinicopathological factors in patients with Crohn's disease (CD) receiving infliximab (IFX) treatment and to develop a new nomogram for predicting outcomes in this population.
methodsThe primary outcome was endoscopic healing (EH) in CD patients receiving IFX at week 30. Logistic regression models were employed to identify predictors of EH. Receiver operating characteristic analysis and calibration plots were used to assess the accuracy and clinical relevance of the developed nomogram.
resultsThis retrospective study included 179 CD patients treated with IFX. Both univariate and multivariate logistic regression identified age (P =.059), platelet-lymphocyte ratio (PLR) (P =.001), anti-drug antibody concentration at 14 weeks (P =.005), IFX concentration at 14 weeks (P =.017) and C-reactive protein level at 14 weeks (P =.001) as independent predictors of EH. A nomogram was constructed based on these factors, its discrimination ability was assessed using area under the curve (AUC) in both the training cohort (N = 126) and validation cohort (N = 53), yielding an AUC of 0.828 (95% CI 0.757-0.899) and 0.731 (95% CI 0.593-0.869), respectively. Decision curve analysis demonstrated the nomogram's clinical utility at risk thresholds above 0.13, with optimal utility between probabilities of 0.13 and 0.94.
conclusionThis TDM- and PLR-based nomogram enables early identification of IFX responders, potentially reducing unnecessary endoscopic evaluations and guiding personalized therapy in CD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.